Gastrointestinal Cancer

2:30
ClarIDHy: updates and initial findings for ivosidenib in CCA
Ghassan Abou-Alfa
1:32
Ghassan Abou-Alfa talks pemigatinib and cabozantinib
Ghassan Abou-Alfa
3:17
Optimism for apatinib in gastric cancer
Steven Norton
4:05
PLATO ACT4 and CORINTH – dosing and novel combination strategies for anal cancers
David Sebag-Montefiore
4:00
Current challenges and key developments in CRC
Kai-Keen Shiu
3:09
Precision medicine in gastrointestinal cancers: promise and pitfalls
Russell Petty
4:31
Colorectal cancer subtyping using a histology based approach
Joanne Edwards
2:13
HER-2 conversion: a phenomenon in trastuzumab resistance
Russell Petty
1:56
ISOPP 2019 reviews ESMO: data highlights
Dharmisha Chauhan
3:45
Molecular target therapy in pancreatic and liver cancer
Hani Babiker
2:54
ILLUMINATE 101: Updates and implications on colorectal cancer
Hani Babiker
3:46
CheckMate 459: updates on nivolumab monotherapy for HCC
Thomas Yau
3:15
Kidney cancer: post-surgery sorafenib
Tim Eisen
0:56
MOUNTAINEER results: trastuzumab and tucatinib for HER2+ mCRC
John Strickler
2:31
IDEA-FRANCE: ctDNA as a predictive value for adjuvant treatment duration
Thierry André
1:15
John Strickler: ESMO 2019 Highlights
John Strickler
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals